Myovant Sciences Ltd
Myovant Sciences Ltd logo
MYOV

Myovant Sciences Ltd (MYOV)

$26.90.34%

Market is closed
– opens on 8 PM, 07 Dec 2022
  • $

1D

1W

1M

1Y

3Y

5Y

Key Stats

$26.81
Day's Range
$26.9
$7.67
52-Week Range
$26.93
1 month return0.49%
3 month return57.8%
1 year return77.67%
5 year return107.99%

Company Information

Myovant Sciences aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy. Myovant Sciences has one FDA-approved medicine, ORGOVYX™ (relugolix), for adult patients with advanced prostate cancer. Its lead product candidate, relugolix combination tablet (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg), is under regulatory review in Europe and the U.S. for women with uterine fibroids and is under development for women with endometriosis. Myovant Sciences is also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, which has completed a Phase 2a study for female infertility as part of assisted reproduction. Sumitovant Biopharma, Ltd., a wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd., is its majority shareholder.
OrganizationMyovant Sciences Ltd
Employees579
CEOMr. David C. Marek
IndustryHealth Technology

Analyst Recommendation

based on 6 analysts ratings

Buy
66%
Buy
33%
Hold
0%
Sell

Based on 6 Wall street analysts offering stock ratings for Myovant Sciences Ltd(by analysts ranked 0 to 5 stars)

Analyst Forecast

What analysts predicted

Upside of 0.41%

Current

$26.89

Target

$27.0

Recommendation Trend

Based on 6 analyst

Current1M Ago3M Ago
Buy
4
10
9
Hold
2
2
3
Sell
0
0
0
Consensus
BUY
BUY
BUY

Company Financials

  • Annual
  • Quarterly

Highlights

Market Capitalization
2.6B
Book Value
$0.19
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-2.22
PEG Ratio
0.0
Wall Street Target Price
27.0

Valuation

Trailing PE0.0
Forward PE0.0
Price/Book (mrq)
70.01
Enterprise Value
2.6B
Enterprise Value/Revenue
7.8
Enterprise Value/Ebitda
-17.35

Technicals

Beta
2.24
50 Day MA
25.01
200 Day MA
16.2

Institutional Holdings

Bellevue Group AG

6.11%

Wellington Management Company LLP

5.65%

HHG PLC

4.08%

State Street Corporation

2.08%

Polar Capital Holdings PLC

2.01%

BlackRock Inc

1.23%

Discover more

Frequently Asked Questions

What is Myovant Sciences Ltd share price today?

Can Indians buy Myovant Sciences Ltd shares?

How can I buy Myovant Sciences Ltd shares from India?

Can Fractional shares of Myovant Sciences Ltd be purchased?

What are the documents required to start investing in Myovant Sciences Ltd stocks?

What are today’s High and Low prices of Myovant Sciences Ltd?

What are today’s traded volumes of Myovant Sciences Ltd?

What is today’s market capitalisation of Myovant Sciences Ltd?

What is the 52 Week High and Low Range of Myovant Sciences Ltd?

How much percentage Myovant Sciences Ltd is down from its 52 Week High?

How much percentage Myovant Sciences Ltd is up from its 52 Week low?

What are the historical returns of Myovant Sciences Ltd?

Who is the Chief Executive Officer (CEO) of Myovant Sciences Ltd?

Trading and brokerage services provided by

Banking and Remittance services provided by

Technology services provided by : Finzoomers Services Private Limited

Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*